Aviva
STOK icon

Aviva’s Stoke Therapeutics STOK Stock Holding History

Aviva’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,272
Closed -$302K – 901
2026
Q1 		$302K Sell
9,272
-6,599
-42% -$216K ﹤0.01% 826
2025
Q4 		$504K Sell
15,871
-6,447
-29% -$194K ﹤0.01% 748
2025
Q3 		$524K Sell
22,318
-21,637
-49% -$371K ﹤0.01% 717
2025
Q2 		$499K Buy
+43,955
New +$417K ﹤0.01% 739
2021
Q2 		– Sell
-30,266
Closed -$1.18M – 970
2021
Q1 		$1.18M Sell
30,266
-6,487
-18% -$369K 0.01% 874
2020
Q4 		$2.28M Sell
36,753
-29,792
-45% -$1.37M 0.01% 661
2020
Q3 		$2.23M Buy
+66,545
New +$1.9M 0.01% 736

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aviva's STOK Position: Q2 2026 in Review

Aviva sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 9,272 shares — an estimated $302K sold.

Aviva first reported a position in STOK in Q3 2020 and held it in 7 quarters. The position peaked at $2.28M in Q4 2020. 198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Aviva reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Aviva sold 9,272 Stoke Therapeutics shares in Q2 2026, an estimated $302K.
  • Aviva first reported a position in Stoke Therapeutics in Q3 2020 and held it in 7 quarters.
  • Aviva's Stoke Therapeutics position peaked at $2.28M in Q4 2020.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.